Amedisys (AMED) | Financial Analysis & Statements
Amedisys Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
621.9M
Gross Profit
273.4M
43.96%
Operating Income
72.7M
11.70%
Net Income
29.1M
4.67%
EPS (Diluted)
$0.84
Balance Sheet Metrics
Total Assets
2.2B
Total Liabilities
940.5M
Shareholders Equity
1.3B
Debt to Equity
0.74
Cash Flow Metrics
Operating Cash Flow
75.5M
Free Cash Flow
66.3M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2024
Amedisys Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.3B | 2.2B | 2.2B | 2.2B | 2.1B |
| Cost of Goods Sold | 1.3B | 1.2B | 1.3B | 1.2B | 1.2B |
| Gross Profit | 1.0B | 990.9M | 962.8M | 980.8M | 886.2M |
| Gross Margin % | 43.3% | 44.3% | 43.3% | 44.3% | 42.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 790.1M | 780.1M | 754.1M | 711.2M | 668.3M |
| Other Operating Expenses | - | - | - | -13.3M | -34.4M |
| Total Operating Expenses | 790.1M | 780.1M | 754.1M | 697.9M | 633.9M |
| Operating Income | 209.6M | 193.1M | 183.8M | 251.9M | 223.4M |
| Operating Margin % | 8.9% | 8.6% | 8.3% | 11.4% | 10.8% |
| Non-Operating Items | |||||
| Interest Income | 8.1M | 3.3M | 178.0K | 49.0K | 292.0K |
| Interest Expense | 30.8M | 31.3M | 22.2M | 9.5M | 11.0M |
| Other Non-Operating Income | -100.7M | -125.4M | -1.5M | 37.8M | -1.9M |
| Pre-tax Income | 86.2M | 39.6M | 160.2M | 280.2M | 210.8M |
| Income Tax | 48.1M | 50.6M | 42.5M | 70.1M | 25.6M |
| Effective Tax Rate % | 55.7% | 127.6% | 26.6% | 25.0% | 12.2% |
| Net Income | 38.2M | -10.9M | 117.7M | 210.2M | 185.2M |
| Net Margin % | 1.6% | -0.5% | 5.3% | 9.5% | 8.9% |
| Key Metrics | |||||
| EBITDA | 292.5M | 271.4M | 256.4M | 361.0M | 296.9M |
| EPS (Basic) | $1.32 | $-0.30 | $3.65 | $6.41 | $5.64 |
| EPS (Diluted) | $1.31 | $-0.30 | $3.63 | $6.34 | $5.52 |
| Basic Shares Outstanding | 32718000 | 32599000 | 32517000 | 32642000 | 32559000 |
| Diluted Shares Outstanding | 32718000 | 32599000 | 32517000 | 32642000 | 32559000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Amedisys Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 303.2M | 126.4M | 40.5M | 42.7M | 81.8M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 296.1M | 313.4M | 296.8M | 275.0M | 255.1M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 7.7M | 8.3M | 6.4M | 5.6M | 4.5M |
| Total Current Assets | 632.1M | 496.9M | 389.0M | 356.7M | 362.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 167.8M | 285.2M | 235.8M | 117.7M | 111.6M |
| Goodwill | 2.5B | 2.6B | 2.7B | 2.5B | 1.9B |
| Intangible Assets | 81.2M | 102.7M | 101.2M | 111.2M | 74.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 15.5M | 16.3M | 17.1M | 17.9M | 65.0M |
| Total Non-Current Assets | 1.5B | 1.6B | 1.6B | 1.5B | 1.2B |
| Total Assets | 2.1B | 2.1B | 2.0B | 1.9B | 1.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 40.0M | 28.2M | 43.7M | 38.2M | 42.7M |
| Short-term Debt | 63.9M | 62.6M | 49.0M | 44.2M | 40.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 106.0M | 102.2M | -9.0M | -3.4M | -3.3M |
| Total Current Liabilities | 514.4M | 473.7M | 355.5M | 374.3M | 456.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 395.4M | 424.6M | 488.9M | 501.4M | 266.5M |
| Deferred Tax Liabilities | 48.1M | 40.6M | 20.4M | 0 | 27.7M |
| Other Non-Current Liabilities | 182.0K | 818.0K | 4.2M | 4.0M | 4.9M |
| Total Non-Current Liabilities | 444.4M | 466.7M | 514.1M | 506.4M | 300.1M |
| Total Liabilities | 958.7M | 940.4M | 869.7M | 880.6M | 756.5M |
| Equity | |||||
| Common Stock | 38.0K | 38.0K | 38.0K | 38.0K | 38.0K |
| Retained Earnings | 791.2M | 747.9M | 757.7M | 639.1M | 430.0M |
| Treasury Stock | 474.9M | 468.6M | 461.2M | 435.9M | 319.1M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.2B | 1.1B | 1.1B | 976.3M | 810.7M |
| Key Metrics | |||||
| Total Debt | 459.3M | 487.2M | 537.9M | 545.6M | 307.0M |
| Working Capital | 117.7M | 23.2M | 33.4M | -17.6M | -94.4M |
Balance Sheet Composition
Amedisys Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 38.2M | -10.9M | 117.7M | 210.2M | 185.2M |
| Depreciation & Amortization | 60.5M | 57.8M | 71.0M | 71.3M | 67.9M |
| Stock-Based Compensation | 30.6M | 29.0M | 16.6M | 23.8M | 26.7M |
| Working Capital Changes | 6.8M | -86.9M | -65.7M | -104.1M | 10.6M |
| Operating Cash Flow | 144.5M | 116.7M | 163.9M | 246.6M | 264.8M |
| Investing Activities | |||||
| Capital Expenditures | -6.6M | -5.5M | -6.1M | -6.2M | -5.3M |
| Acquisitions | -1.0M | 47.4M | -72.6M | -270.2M | -281.1M |
| Investment Purchases | 0 | 0 | -15.0M | -5.0M | -875.0K |
| Investment Sales | 0 | 150.0K | 0 | 0 | - |
| Investing Cash Flow | -7.5M | 42.2M | -93.4M | -281.2M | -287.1M |
| Financing Activities | |||||
| Share Repurchases | -6.2M | -6.5M | -25.3M | -116.8M | -54.5M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 23.0M | 534.5M | 791.0M | 684.2M |
| Debt Repayment | 0 | -23.0M | -534.5M | -551.7M | -703.2M |
| Financing Cash Flow | -49.2M | -90.2M | -36.6M | -1.9M | -43.9M |
| Free Cash Flow | 214.3M | 124.5M | 126.1M | 182.2M | 283.6M |
| Net Change in Cash | 87.7M | 68.6M | 33.9M | -36.4M | -66.2M |
Cash Flow Trend
Amedisys Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
39.30
Forward P/E
19.76
Price to Book
2.69
Price to Sales
1.38
PEG Ratio
-2.78
Profitability Ratios
Profit Margin
3.56%
Operating Margin
11.70%
Return on Equity
6.67%
Return on Assets
6.52%
Financial Health
Current Ratio
1.36
Debt to Equity
35.34
Beta
0.90
Per Share Data
EPS (TTM)
$2.57
Book Value per Share
$37.48
Revenue per Share
$73.28
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AMED | 3.3B | 39.30 | 2.69 | 6.67% | 3.56% | 35.34 |
| HCA Healthcare | 106.0B | 16.86 | -38.44 | -244.82% | 8.97% | -17.57 |
| Encompass Health | 10.2B | 18.52 | 4.21 | 24.82% | 9.54% | 82.85 |
| Ensign Group | 11.1B | 32.78 | 4.95 | 16.90% | 6.80% | 98.70 |
| DaVita | 10.0B | 16.32 | 9.13 | 64.85% | 5.47% | 1,111.35 |
| Chemed | 5.6B | 20.88 | 5.36 | 25.28% | 10.48% | 14.68 |
Financial data is updated regularly. All figures are in the company's reporting currency.
